セラノスティクス横浜がお届けする最新のセラノスティクス　セラヨコ・ライブラリー

Information
2025.03.24　
サイトを公開しました。

文献のご紹介　※セラヨコ・トーク付き

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on (“8Ga]Ga-PSMA-11 PET/CT in the proPSMA Study

J Nucl Med 2025; 66:713-718
DOI　10.2967/
jnumed.124.268901

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Journal of Nuclear Medicine September 2024, jnumed.124.268020;
DOI 10.2967/
jnumed.124.268020

The tumor sink effect on PSMA-PET/CT in metastatic prostate cancer and its implications for PSMA-RLT: insight from the 3TMPO study

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy

Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00249-9.
DOI　10.1016/
j.euo.2024.11.002. Online ahead of print.

Prostate-specific Membrane Antigen Reporting and Data System Version 2.0

DOI　0.1016/
j.eururo.2023.06.008

Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET

Journal of Nuclear Medicine February 2025, jnumed.124.268340;
DOI　10.2967/
jnumed.124.268340

61Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging

DOI　10.2967/
junmed.123.267126

Low-and High- Volume Disease in Mertastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study

Journal of Nuclear Medicine January 2025, 66 (1) 54-60;
DOI 10.2967/
jnumed.124.268441

1 2 次へ »

※セラヨコ・トーク＝抄読会でのセラヨコメンバーのつぶやき

動画コンテンツ